Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

Por Meihua Wang, Cong Chen, Thomas Jemielita, James Anderson, Xiaoyun (Nicole) Li, Chen Hu, S. Peter Kang, Nageatte Ibrahim, Scot Ebbinghaus
Publicado em 2019-02-01

P-275 First-line pembrolizumab versus investigator-choice chemotherapy for mismatch repair–deficient or microsatellite instability–high metastatic colorectal carcinoma: randomized,...

Por Luis, Diaz, Dung, Le, Takayuki, Yoshino, Thierry, André, Johanna, Bendell, Minori, Koshiji, Yinghua, Zhang, Peter, Kang S., Bao, Lam, Dirk, Jäger
Publicado no Ann Oncol (2016)

P-274 Pembrolizumab for patients with previously treated, mismatch repair–deficient microsatellite instability–high advanced colorectal carcinoma: phase 2 KEYNOTE-164 study

Por Dung, Le, Thierry, André, Won, Kim Tae, Eric, Van Cutsem, Dirk, Jäger, Ravit, Geva, Hiroki, Hara, You, Kim Tae, Takayuki, Yoshino, Matthew, Burge, Hiroya, Taniguchi, Elena, Elez, Chloe, Atreya, Johanna, Bendell, Minori, Koshiji, Ruixue, Wang, Peter, Kang S., Luis, Diaz
Publicado no Ann Oncol (2016)